NEURELIS TO PRESENT NINE POSTERS AT THE 76th AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
Investigational Phase 3 study of VALTOCO® (diazepam nasal spray) CIV shows double the time between seizure clusters when administered over a 12-month period Poster addresses myths associated with rescue therapy for seizure clusters Additional poster highlights investigational non-surgical treatment option for cerebral cavernous malformations SAN DIEGO, CA — December 2, 2022 — Neurelis, Inc., announced […]